Identification of HER2-over-expression, HER2-low-expression, and HER2-zero-expression statuses in breast cancer based on F-FDG PET/CT radiomics.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
PMID: 40355910

Abstract

PURPOSE: According to the updated classification system, human epidermal growth factor receptor 2 (HER2) expression statuses are divided into the following three groups: HER2-over-expression, HER2-low-expression, and HER2-zero-expression. HER2-negative expression was reclassified into HER2-low-expression and HER2-zero-expression. This study aimed to identify three different HER2 expression statuses for breast cancer (BC) patients using PET/CT radiomics and clinicopathological characteristics.

Authors

  • Xuefeng Hou
    Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin, 300060, China.
  • Kun Chen
    Department of Anesthesiology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
  • Huiwen Luo
    Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin, 300060, China.
  • Wengui Xu
    Department of Molecular Image and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
  • Xiaofeng Li
    Department of Otorhinolaryngology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, China.

Keywords

External Resources

Popular Topics
Recent Journals